Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

(marketscreener.com) Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical TrialMELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the approval of its Investigational...https://www.marketscreener.com/quote/stock/ALTERITY-THERAPEUTICS-LIM-57143028/news/Alterity-Therapeutics-Receives-U-S-FDA-Approval-for-Investigational-New-Drug-Application-for-ATH434-41816441/?utm_medium=RSS&utm_content=20220920